EA004870B1 - Способ обезболивания - Google Patents

Способ обезболивания Download PDF

Info

Publication number
EA004870B1
EA004870B1 EA200300172A EA200300172A EA004870B1 EA 004870 B1 EA004870 B1 EA 004870B1 EA 200300172 A EA200300172 A EA 200300172A EA 200300172 A EA200300172 A EA 200300172A EA 004870 B1 EA004870 B1 EA 004870B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pain
cancer
tetrodotoxin
ttx
sodium channel
Prior art date
Application number
EA200300172A
Other languages
English (en)
Russian (ru)
Other versions
EA200300172A1 (ru
Inventor
Квингбин Донг
Фрэнк Хэйконг Шам
Original Assignee
Уэкс Медикал Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уэкс Медикал Лимитед filed Critical Уэкс Медикал Лимитед
Publication of EA200300172A1 publication Critical patent/EA200300172A1/ru
Publication of EA004870B1 publication Critical patent/EA004870B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Laser Surgery Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
EA200300172A 2000-09-18 2001-09-11 Способ обезболивания EA004870B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB001245171A CN1284536C (zh) 2000-09-18 2000-09-18 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
PCT/CN2001/001391 WO2002022129A1 (en) 2000-09-18 2001-09-11 A method of analgesia

Publications (2)

Publication Number Publication Date
EA200300172A1 EA200300172A1 (ru) 2003-12-25
EA004870B1 true EA004870B1 (ru) 2004-08-26

Family

ID=4590472

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300172A EA004870B1 (ru) 2000-09-18 2001-09-11 Способ обезболивания

Country Status (26)

Country Link
US (1) US6407088B1 (https=)
EP (3) EP1320369B1 (https=)
JP (1) JP2004508404A (https=)
KR (2) KR20070112864A (https=)
CN (1) CN1284536C (https=)
AT (2) ATE447959T1 (https=)
AU (1) AU2002213785A1 (https=)
BG (1) BG107690A (https=)
BR (1) BR0113961A (https=)
CA (1) CA2421562C (https=)
DE (1) DE60140466D1 (https=)
EA (1) EA004870B1 (https=)
EE (1) EE200300106A (https=)
ES (1) ES2435463T3 (https=)
HR (1) HRP20030202A2 (https=)
HU (1) HUP0302677A3 (https=)
IL (1) IL154342A0 (https=)
IS (1) IS6719A (https=)
MX (1) MXPA03002389A (https=)
NO (1) NO323960B1 (https=)
PL (1) PL360616A1 (https=)
SK (1) SK3732003A3 (https=)
UA (1) UA76960C2 (https=)
WO (1) WO2002022129A1 (https=)
YU (1) YU17103A (https=)
ZA (1) ZA200301852B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500590A (en) 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
WO2003047589A1 (en) * 2001-11-15 2003-06-12 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
WO2004013637A1 (en) * 2002-08-01 2004-02-12 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
EP1589959A2 (en) * 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
WO2005110417A1 (en) * 2004-05-07 2005-11-24 Phytotox Limited Phycotoxins and uses thereof
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
CN100363006C (zh) * 2004-08-20 2008-01-23 厦门朝阳生物工程有限公司 一种戒毒制剂及其制备方法
EP1799219A1 (en) * 2004-09-21 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
CA2581083A1 (en) * 2004-09-22 2006-03-30 Helmut Henrich Buschmann Tetrodotoxin and its derivatives for the treatment of peripheral-nervously derived neuropathic pain
EP1690541A1 (en) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency
TW200640463A (en) * 2005-02-11 2006-12-01 Esteve Labor Dr Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1714655A1 (en) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
WO2007025212A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
WO2007025213A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the management of musculoskeletal pain
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1844781A1 (en) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of preterm labor
WO2007110220A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
EP1844782A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
EP1844783A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel - subunit Nav1.6
EP2012774A1 (en) * 2006-03-27 2009-01-14 Wex Pharmaceuticals, Inc Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
EP1882692A1 (en) * 2006-07-28 2008-01-30 Wex Pharmaceuticals Inc. Dimethano-[1,3]dioxocino[6,5-D]pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain
EP2173167A4 (en) * 2007-07-06 2010-07-28 Nuon Therapeutics Inc TREATMENT OF NEUROPATHIC PAIN
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
WO2010117996A1 (en) * 2009-04-08 2010-10-14 Children's Medical Center Corporation Prolonged duration local anesthesia with minimal toxicity
ES2484315T3 (es) 2010-02-10 2014-08-11 Phytotox Limited Tratamiento de la pérdida del sentido del tacto con derivados de saxitoxina
CN103328038A (zh) 2010-12-01 2013-09-25 史拜诺莫度雷森公司 向神经解剖结构直接递送药剂
CN105189553A (zh) 2013-03-14 2015-12-23 瑞泽恩制药公司 Nav1.7的人抗体
TR201903411T4 (tr) 2013-03-15 2019-04-22 Childrens Medical Ct Corp Uzun süreli lokal anestezi için neosaksitoksin kombinasyon formülasyonları.
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药
CA3215362A1 (en) 2021-04-23 2022-10-27 Meng Zhou Tetrodotoxin liquid formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
AU1888195A (en) * 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
WO1998051290A2 (en) * 1997-05-16 1998-11-19 Children's Medical Center Corporation Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Also Published As

Publication number Publication date
HRP20030202A2 (en) 2005-02-28
SK3732003A3 (sk) 2005-05-05
EP2298306B1 (en) 2013-09-11
ES2435463T3 (es) 2013-12-19
PL360616A1 (en) 2004-09-20
NO323960B1 (no) 2007-07-23
EP1563839B1 (en) 2012-01-25
IL154342A0 (en) 2003-09-17
KR100891568B1 (ko) 2009-04-03
EP1320369A4 (en) 2003-07-02
YU17103A (sh) 2006-03-03
ATE447959T1 (de) 2009-11-15
HUP0302677A2 (hu) 2003-11-28
CA2421562A1 (en) 2002-03-21
CA2421562C (en) 2011-05-24
ZA200301852B (en) 2004-06-21
EA200300172A1 (ru) 2003-12-25
EP1320369A1 (en) 2003-06-25
NO20030915L (no) 2003-04-25
CN1284536C (zh) 2006-11-15
CN1356104A (zh) 2002-07-03
WO2002022129A1 (en) 2002-03-21
EP2298306A1 (en) 2011-03-23
IS6719A (is) 2003-02-14
MXPA03002389A (es) 2004-03-12
JP2004508404A (ja) 2004-03-18
AU2002213785A1 (en) 2002-03-26
BG107690A (bg) 2004-01-30
HUP0302677A3 (en) 2005-01-28
NO20030915D0 (no) 2003-02-27
US6407088B1 (en) 2002-06-18
EP1563839A1 (en) 2005-08-17
KR20030034181A (ko) 2003-05-01
ATE542534T1 (de) 2012-02-15
BR0113961A (pt) 2004-01-13
UA76960C2 (en) 2006-10-16
EE200300106A (et) 2005-04-15
DE60140466D1 (de) 2009-12-24
KR20070112864A (ko) 2007-11-27
EP1320369B1 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
EA004870B1 (ru) Способ обезболивания
JP6673924B2 (ja) 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
EA002554B1 (ru) Применение кабэрголина при лечении синдрома усталых ног
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
US20250345433A1 (en) Drug For Treating Disorders Of An Organ Or Tissue Function And Diseases Accompanied By Such Disorders, And The Method For Obtaining It
WO2022253034A1 (zh) 吡咯并嘧啶类化合物的用途
CN108686023A (zh) 一种治疗老年性皮肤瘙痒的止痒润肤精油
US11660275B2 (en) Epilepsy treatment agent
US11564958B2 (en) Compositions and methods of treatment of Ehlers-Danlos syndromes
EA008339B1 (ru) Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
Jones Facial Diplegia in the Guillain—Barré Syndrome
AU2007200073B2 (en) A Method of Analgesia
JP2024165960A (ja) 急性痛の治療剤
Aishwarya A Clinical study on siddha herbal formulation Kukkilathy Chooranam in Ratha Moolam (Bleeding Piles)
Propert Lipoid pneumonia
WO2010120203A1 (ru) Применение органических красителей в качестве обезболивающих средств
Schwartz et al. Hypercalcemia and hypocalcemia
Shah Master of Veterinary Sciences
Ross et al. Osteoarthritis of the Knee
US20230037437A1 (en) Formulations for use in the treatment of different types of addictions and dependence on addictive substances
CN101411700A (zh) 5,7,4’-三羟基二氢黄酮或其衍生物用于止痛的用途